Blood-based biomarker discovery with gene expression profiling has been hampered by interference from endogenous, highly abundant ␣-and ␤-globin transcripts. We describe a means to quantify the interference of globin transcripts on profiling and the effectiveness of globin transcript mitigation by (a) defining and characterizing globin interference, (b) reproducing globin interference with synthetic transcripts, and (c) using ROC curves to measure sensitivity and specificity for a protocol for removing ␣-and ␤-globin transcripts.
Gene expression profiling of peripheral blood can be a powerful tool for biomarker discovery in clinical trials (1) (2) (3) (4) . Although peripheral blood samples are collected routinely in clinical practice, maintaining RNA integrity in such samples and stabilizing their biological signatures have proved difficult. A widely used method for obtaining total RNA from leukocytes requires isolating peripheral blood mononuclear cells (PBMCs) 3 by density-gradient centrifugation, which requires both instrumentation beyond what is available in the typical clinical setting and manipulations of 1-2 h that may cause interfering signatures (5 ) .
To reduce the occurrences of such signatures, investigators have introduced technologies that decrease the time between blood draw and RNA stabilization [e.g., PAXgene (PreAnalytiX), Tempus (Applied Biosystems)]. Although these systems may stabilize RNA at the point of collection, they introduce interfering signatures because of the abundance and variability in the amounts of ␣-and ␤-globin mRNA, which obscure signatures of biological interest (1, 6, 7 ) . The degree of globin message representation in mRNA in whole blood can vary widely, with globin mRNA species constituting up to 70% of whole-blood mRNA in patients with high reticulocyte counts (8 ) . We describe methods for quantifying and characterizing the globin message in samples, how to recognize a globin messageinduced signature in profiling data, and the efficacies of measures for mitigating interference by globin messages.
Materials and Methods
We describe samples, processing methods, pooling strategies, and experimental-design features for generating data that quantify globin RNA interference and its mitigation. Our strategy consists of pooling samples of total RNA to make homogeneous samples of RNA populations that we can supplement with different concentrations of globin transcripts, characterizing the degree of interference by the globin message, and measuring the effects of measures of globin transcript mitigation on expression profiles. We also used an RNA pool with endogenous globin transcripts to measure how mitigation measures affect the ability to detect an exogenous RNA signature (from brain tissue).
BLOOD COLLECTION AND EXTRACTION OF TOTAL RNA
We drew blood samples from volunteers after they had provided informed consent and the protocols had been approved. At site A (BSC Labs), 1 unit of whole blood was drawn from each of 10 healthy donors and preserved with EDTA. We filled 20 PAXgene tubes (VWR catalog no. 77776 -026) for subsequent extraction of total RNA (sample sets A and D). The EDTA-preserved blood (75 mL) was added to 3 Accuspin tubes (SigmaAldrich, catalog no. A7054) within 2 h of collection for PBMC isolation and extraction of total RNA (sample set E) with an in-house semiautomated procedure that follows the protocol (9 ) accompanying the PAXgene 96 Blood RNA Kit (Qiagen, catalog no. 762331). We conducted no additional purification steps before treating samples with GLOBINclear (Ambion). At site B, we drew blood directly into 10 PAXgene tubes for each of 10 healthy donors and extracted total RNA (sample sets B and C). We created intradonor pools for each donor/extraction protocol set (see Pooling and Supplementation Strategy and Fig. 1 ).
SUPPLEMENTATION WITH GLOBIN TRANSCRIPTS
We added ␣-and ␤-globin transcripts to human whole-blood samples containing total RNA and used these supplemented samples to quantify the reduction in the globin message and the mitigation of the interference. We used multiple sequences of globin transcripts in the NCBI Reference Sequence collection (RefSeq) to construct consensus sequences for ␣-and ␤-globin mRNA (see Figs. 1 and 2 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/issue2) and added 30 nucleotides of poly(A) 3Ј to the sequence. We then submitted these sequences to Blue Sky Biotech for subcloning and in vitro transcription. They isolated full-length clones, subcloned them, and sequenced the clones for verification. After we verified the transcript sequences with our RefSeq consensus, a sequence analysis identified a point mutation in the 3Ј untranslated region of the ␤-globin clone that coincided with the array probe for the ␤-globin transcript; regardless, the array probe was saturated because of the abundance of the ␤-globin message.
SUPPLEMENTATION WITH HUMAN BRAIN TOTAL RNA
We obtained human brain total RNA from BioChain (catalog no. R1234035-50, lot no. A703158) and added it to aliquots of peripheral blood total RNA at the following concentrations: 0 mg/g, 0.5 mg/g, and 5 mg/g. We then used the resulting exogenous brain RNA signature and ROC curve analysis to evaluate the sensitivity and specificity of each mitigation protocol (10 ).
GLOBIN TRANSCRIPT MITIGATION
Ambion's GLOBINclear product, a globin transcriptmitigation technology for removing ␣-and ␤-globin transcripts, is used to pretreat total RNA before amplifying a target. We precipitated a 2-g aliquot of each sample in ethanol, resuspended the sample in 14 L water, and processed the sample with the GLOBINclear kit according to the manufacturer's protocol (11 ) . In brief, we mixed custom biotinylated oligonucleotides complementary to globin RNA sequences with RNA prepared from blood samples and annealed the oligonucleotides to ␣-and ␤-globin transcripts. We then added streptavidin-coated paramagnetic beads to bind the biotinylated duplexes and remove the captured globin transcripts from the preparations of total RNA, adjusted the GLOBINclear-treated samples of total RNA to 150 L, and used aliquots for quantitative reverse transcription-PCR (qRT-PCR) and microarray experiments.
POOLING AND SUPPLEMENTATION STRATEGY
Characterization of globin transcript interference in microarray data (sample sets A and B). We used several pooling strategies to generate reference channels for the 2-color array format used in this study. In one strategy (Fig. 1A) , we pooled total RNA extracted from blood that had been aliquoted into PAXgene tubes from a given donor, combined copy RNA (cRNA) generated from each donor pool of total RNA to form a multidonor pool [also referred to as a mass-balanced, self-referenced pool (10 ) ] to make interdonor comparisons, and compared each donor with the pool. We used the resulting hybridization data to characterize globin transcript interference. We used this pooling strategy with sample sets A and B to quantify such in-terference, with 2 separate interdonor comparisons as examples.
Creating and mitigating interference by synthetic globin transcripts (sample set C). In another strategy (Fig. 1B) , we combined total RNA from multiple donors to create a multidonor pool for supplementation experiments. We split aliquots of pooled total RNA into separate containers to which we had added a titration of synthetic globin transcripts. We generated cRNA from each supplemented sample and formed a massbalanced, self-referenced pool from all cRNA preparations for fluor-reverse pairing in hybridization experiments. We used sample set C to quantify the effects of globin transcript mitigation on microarray data via comparison with untreated samples.
Mitigation of an endogenous globin interference (sample sets D and E).
In the third set of experiments, we quantified the effect of endogenous globin interference on the ability to recover an exogenous brain signature. Sample sets D and E were formed according to the pooling scheme summarized in Fig. 1C . We split a donor sample into aliquots and added different known amounts of brain RNA into the individual aliquots. cRNA was made from each aliquot, and a self-referenced pool of all donors was made from cRNA synthesized from aliquots with no added brain RNA. We hybridized cRNA from the supplemented samples against cRNA synthesized from samples with no supplemented brain RNA and measured the ability to identify brain-specific sequences for (A), sample processing for creating and assessing an endogenous interference. Blood was first drawn from each donor into an EDTA-containing bag to obtain a volume sufficient for the experiment and then transferred into PAXgene tubes for stabilization. Total RNA was extracted from the samples in PAXgene tubes and pooled for each donor. Donor pools were amplified and hybridized against a multidonor cRNA pool in fluor-reverse pairs (FRPs). (B), sample processing for creating and assessing an exogenous interference. RNA from blood tubes was extracted and combined into a single all-donor pool, which was then split and used as the reference for hybridization experiments with samples supplemented with globin transcripts. (C), Splitting of donor sample to create brain RNA supplementation sets (0, 0.5, and 5.0 mg/g total RNA) to evaluate sensitivity. Supplement pools were amplified and hybridized in FRPs against a cRNA pool containing no supplement.
sample sets D and E, with and without mitigation of globin mRNA.
QRT-PCR ANALYSIS WITH TAQMAN AND SYBR GREEN
We selected primer sets targeted to the second intron/ exon junctions of both ␣-and ␤-globin mRNA. We submitted sequences for 200-nucleotide stretches spanning intron/exon junction 2 of ␣-and ␤-globins to Applied Biosystems' Assay-by-Design service for TaqMan primer/probe sets, which produced the following forward, reverse, and reporter ␣-globin sequences, respectively: 5Ј-GCACGCGCACAAGCT-3Ј, 5Ј-GGGTCACCAGCAGGCA-3Ј, and 5Ј-ACTTCAA GCTCCTAAGCCAC-3Ј. The forward, reverse, and reporter ␤-globin sequences were 5Ј-AAGCTGCA CGTGGATCCT-3Ј, 5Ј-GATGGGCCAGCACACAGA-3Ј, and 5Ј-CCCAGGAGCCTGAAGTT-3Ј, respectively. We also used these primers for SYBR Green qRT-PCR analysis. For total RNA and cRNA, we used Applied Biosystems' High Capacity Archive Kit (catalog no. 4322171) with 10 ng of each sample to generate T7-dT-primed cDNA. In short, total RNA was dried down and resuspended in 20 L master mix containing 1ϫ deoxynucleoside triphosphates and 1ϫ RT buffer, 50 U Multiscribe TM , 40 U RNase OUT (Invitrogen, catalog no. 10777-019) and 5 pmol oligo-dT (Ambion, catalog no. AM5730G). Reactions were carried out on a DNA Engine Tetrad (MJ Research) at 70°C for 5 min, 37°C for 120 min, and 95°C for 5 min).
We conducted quadruplicate TaqMan or SYBR Green assays with 100-pg cDNA aliquots and the primer or probe, respectively. We carried out all reactions simultaneously in an Applied Biosystems 7900HT Fast Real-Time PCR System and calculated results by means of a relative-abundance method (12, 13 ) .
SAMPLE AMPLIFICATION AND MICROARRAY ANALYSIS
We profiled and analyzed samples of total RNA extracted from human whole blood (14, 15 ) . In brief, we amplified total RNA from blood by means of a modified 2-round reverse transcription reaction mediated by Moloney murine leukemia virus reverse transcriptase, followed by in vitro transcription and labeling with a Cy dye. Samples were hybridized to custom 25 000 -probe oligonucleotide arrays (Agilent Technologies) in fluor-reverse pairs. Scanned microarray images were processed with a feature extractor developed in house with MATLAB (The MathWorks). The feature extractor automatically locates the arrayed features on a scanned image, calculates the mean pixel intensity for each feature, and flags features that either show artifacts or have intensities at the scanner's background or saturation level. Feature intensities normalized by the mean intensity of the nonflagged features for the Cy3 and Cy5 channels are used to form ratios of the 2 channels for each reporter. An in-house error model based on a null hypothesis of no differential regulation was used to assess the significance of an observed ratio (16 ) . Hybridization-ratio data were analyzed with MATLAB.
Results

CHARACTERIZATION OF GLOBIN TRANSCRIPT INTERFERENCE IN MICROARRAY DATA
We first encountered globin transcript interference with microarray data from healthy donors during expression profiling of blood donor variability. We found globin mRNA interference in 2 separate sets of donor samples (Fig. 2) . Fig. 2A is a 1-D agglomerative cluster of a panel of 7 (of a total of 10) donor blood samples from sample set A; all 7 samples were hybridized against a mass-balanced, self-referenced pool (16 ) . The probe content chart on the horizontal axis displays the window-averaged nucleotide count (labeled A, T, C, and G) for each probe ordered by the 1-D clustering algorithm. We used these charts to assess possible content bias in clusters. For example, we observe in Fig. 2A that the GC content per probe to the left of the yellow (dot-dash) line is approximately 35% higher than the GC content of probes to the right of the line. Nonspecific probe-target annealing has been associated with a high GC content of probes (17 ) .
We have arranged the experiments summarized in Fig. 2, A and B , on the vertical axis in descending order of qRT-PCR-derived globin transcript content. This ordering shows the interference as a globin contentdependent pattern of gene regulation. One can divide the pattern into 2 regions: cross-hybridization and normalization ( Fig. 2A) . We call cross-hybridization a clustering of differentially expressed genes that can be associated with AT-poor/GC-rich probes when experiments are arranged in order by globin mRNA content in heat maps. Within the constraints of the 3Ј-biased probe selection, we obtained approximately 1250 cross-hybridization genes (P Ͻ0.01) and have observed gene sets as large as 2500 in more severe cases (data not shown). In ratio-based microarray experiments, we used the mean intensity of all biological features to normalize feature intensities in each channel over the entire chip (16 ) . In this case, the intensity due to cross-hybridization is sufficient to skew channel normalization, producing an "inverse" effect. In other words, for a set of genes found to be up-regulated because globin transcript cross-hybridization, there is another set of genes calculated to be downregulated, compensating for the skewed signal levels. In this sense, the normalization effect is a consequence of globin transcript cross-hybridization interference.
Specifically, sample set B has fewer than 250 crosshybridization genes, compared with 1250 in sample set A. Consequently, the normalization interference is not as pronounced in sample set B, and the globindependent pattern is not as robust.
To investigate further the difference between the sample sets, we analyzed the qRT-PCR data and their relationship to the microarray data. Fig. 2C is a bar chart of the qRT-PCR data for sample sets A and B and is arranged by globin transcript content. We note that the overall content of ␣-and ␤-globin transcripts as a percentage of total RNA is higher in sample set A. Furthermore, sample set A shows an absolute difference of approximately 3% in the proportion of globin RNA between the samples with the highest and lowest proportions (approximately 4.5% and approximately 1.5%, respectively; Fig. 2C ), which represents a 3-fold change in the relative amount of globin transcripts. We see with sample set B a corresponding absolute change of 0.7% or a relative change of just over 2-fold (approximately 1.3% and 0.6%, respectively). This analysis reveals that the total abundance of and variation in globin RNA content for sample set A is greater than for sample set B.
In Fig. 2D , we show how globin mRNA concentration expressed as a percentage of total RNA (as measured by qRT-PCR) correlates with the mean log ratio (MLR) for ␣-globin, ␤-globin, and -globin (an em- 1-D agglomerative clusters of self-referenced hybridizations according to treatment group. Experiments are sorted by the concentration of supplemented globin mRNA relative to the total RNA concentration. Each plot has the same gene set and order.
Transcripts that were differentially regulated by 2-fold were selected to go into the no-treatment heat map; the same set of transcripts is represented in the GLOBINclear heat map. Signature counts for each supplement level are noted at the side of each heat map. The nucleotide compositions of the probes are noted above each plot. Cross-hybridization and normalization interferences are demarcated by hatched yellow lines. a Combined ␣-globin and ␤-globin message in total RNA and cRNA were quantified by qRT-PCR analysis of sample set C. Values are normalized to the input reaction mass; results were calculated by a relative-abundance method ͓Livak and Schmittgen (11 ), Schmittgen et al. (12 )͔. Data are presented as the mean (SD) (n ϭ 4). b NA, not applicable. data in Fig. 2 , we conclude that qRT-PCR of HBE1 4 (hemoglobin, epsilon 1) MLR data can be used to assess the likelihood of globin transcript interference in a sample set.
CREATING AND MITIGATING THE INTERFERENCE BY SYNTHETIC GLOBIN RNA
To characterize the interference further and assess potential mitigation technologies, we developed a means to reliably recreate globin RNA interference by titrating synthesized globin gene transcripts into a background of total RNA extracted from pooled samples of whole blood. We measured the ratio of ␣-globin mRNA to ␤-globin mRNA for donor sets A and B via qRT-PCR analysis of total RNA. For each donor, we measured a consistent ␣-globin/␤-globin mRNA ratio of 3:1 [for example, the mean ␣-globin/␤-globin mRNA ratio for the data in Fig. 2C was 74.6:25.4 (n ϭ 17), CV ␣ ϭ 3%, and CV ␤ ϭ 9%]. We used this ratio for our globin mRNA-supplementation experiments. To the same parent pool of total RNA, we added synthesized globin RNA to concentrations of 0, 10, 25, 40, and 70 mg/g total RNA (sample set C). For simplicity, we refer to the experimental points by the supplementation amounts. Our intent was to create substantial interference because the highest proportion of endogenous globin RNA that we had previously encountered was 65 mg/g of the total RNA (data not shown). We also wanted to ensure large variation in the globin RNA content within a sample set.
For sample set C, we divided each sample into 2 aliquots, one of which we treated with GLOBINclear and the other we left untreated. BioAnalyzer traces with the RNA 6000 Pico LabChip (Agilent Technologies) showed that GLOBINclear effectively eliminates the globin RNA peak at all supplementation levels (see Fig. 3 in the online Data Supplement). Furthermore, a qRT-PCR analysis of total RNA before and after treatment demonstrates a reduction of representation in all samples (Table 1 ). In particular, 97% ( ϭ 0.23%) of the globin in the sample supplemented with globin mRNA at 70 mg/g was removed from total RNA. Absolute representation was reduced for all globin RNA 4 Human genes: HBE1, hemoglobin, epsilon 1. additions by at least 94% of the original content. Not only are the magnitudes of globin mRNA representation lowered overall, but the difference between the samples with highest and lowest globin mRNA content (␣-globin plus ␤-globin) was also greatly reduced after GLOBINclear treatment. We then amplified treated and untreated samples for 2 independent self-referenced pool hybridization plans (Fig. 1B) . We quantified the globin transcript content of the cRNA produced, including the selfreferenced pools, with the same globin transcript assays used with total RNA. Table 1 shows that the amplification product increases as the amount of added globin RNA increases. In addition, the self-referenced pool has the approximate mean globin transcript content (approximately 25 mg/g) expected from mixing the total set of supplemented samples together. We conclude from these data that GLOBINclear-treated samples have substantially reduced globin message, both in the starting total RNA and in the subsequent cRNA product. We hybridized samples according to a self-referenced pool scheme. We found in array hybridization data (Fig. 3) that a 1-D agglomerative cluster for the untreated controls (left heat map) demonstrated globin message interference; that is, a large signature (Ͼ1500 genes, P Ͻ0.01) correlated with Apoor/GC-rich probes and a corresponding normalization effect. The magnitudes and directions of the interference signatures correlate with the supplement quantity. A comparison with the GLOBINcleartreated sample (right heat map) demonstrates that the interference is essentially eliminated. Whereas the mean number of signatures per supplement for the untreated sample panel was 1126, the GLOBINcleartreated sample set had a mean of 210 signatures, a difference that is statistically significant (P Ͻ0.01). The remnant GLOBINclear signatures do not correlate with the A-poor/GC-rich probes and represent Ͻ1% of the total features differentially detected.
MITIGATION OF INTERFERENCE BY ENDOGENOUS GLOBIN
TRANSCRIPTS
To quantify mitigation strategies for a traceable endogenous signature, we created sample sets D and E. We supplemented donor total RNA with brain total RNA (0, 0.5, and 5.0 mg/g) and then treated this sample set with GLOBINclear or not. In addition, we created sample set E (see Materials and Methods) as a reference for globin transcript mitigation. We processed each sample set as depicted in Fig. 1C , with the modification that the reference pool was not supplemented with brain RNA. This strategy induced a signature in total RNA from blood. Fig. 4 is a combined 1-D agglomerative cluster with experiments organized first into 3 groups by treatment (no mitigation, GLOBINclear, PBMCs) and then by HBE1 MLR, according to the no-mitigation protocol. The cross-hybridization and normalization effects are marked in the figure. Without mitigation, there is substantial interference when the data are ordered by HBE1 expression. GLOBINclear treatment significantly reduces both globin message and normalization interferences to background levels (from approximately 1200 signatures to 0; P ϭ 0.01).
Next, we identified a brain signature (18, 19 ) (Fig. 4 inset) . We used ROC curve analysis to measure the impact of GLOBINclear treatment on sensitivity and specificity, relative to the brain signature (Fig. 5) . We specifically compared nontreated samples with GLOBINclear-treated samples and PBMC samples with respect to the 0.5-mg/g brain signature. The sensitivity and specificity of GLOBINclear approach those obtained with PBMCs and show a nominal improvement over no treatment. Each curve in the figure represents the mean of 36 arrays (9 samples, 4 arrays) for a given sample condition.
Discussion
The desire to use human whole blood collected in clinical settings for microarray profiling and biomarker discovery has stimulated the commercial development of several technologies that stabilize RNA and mitigate interference by globin transcripts. We selected PAXgene blood-collection tubes, Ambion's GLOBINclear technology, and the Agilent Technologies microarray platform to characterize reagents and methods for the purposes of quantifying a globin message-induced interference and investigating its mitigation. The development of reproducible interference with synthetic globin transcripts was critical to evaluating globin interference-mitigation strategies. Throughout this study, we used these reagents in a model that was not influenced by the variability in donor samples. We used qRT-PCR and BioAnalyzer analyses in conjunction with heat maps, cross-hybridization analyses, and ROC curve analysis to confirm that a commercially available kit could mitigate interference by synthetic globin message. Our application of the technology to a "natural" endogenous interference demonstrates the potential usefulness of the tools developed in our investigation of this approach. We confirmed the observation (20 ) that both the absolute concentration of globin transcripts and the difference in transcript concentrations within a sample set are factors in causing interference. We conclude that the methods and reagents we have developed may be useful quantitative tools for characterizing globin mRNA interference and its mitigation. 
